** Brokerage Jefferies starts coverage on ophthalmic medical device company Rxsight RXST.O with "buy" rating and sets PT at $50
** New PT more than double the stock's last close
** Brokerage says RXST's competitive moat is strong, with significant growth potential and minimal competition expected in the next 5 years
** Sees upside in the company's light adjustable lenses (LALs) used in cataract surgery; says the procedure is highly profitable for surgeons
** LALs allow post-implantation adjustments unlike traditional lenses
** 8 out of 10 brokerages rate the stock "buy" or higher, 2 rate "hold" and median PT is $43 - LSEG data
** RXST stock down 51% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.